Platinum+
Presentation Title: Strategic approach for early stage EGFRm NSCLC patient
Chair: Ki Hyeong Lee (Chungbuk National University Hospital, Korea)
Speaker: Min Hee Hong (Yonsei Cancer Center, Korea)
| Address | 21F, ASEM Tower, 517 Yeongdongdaero, Gangnam-gu, Seoul, Korea | ||
|---|---|---|---|
| Telephone | +82-2-2188-0800 | Fax | +82-2-2188-2111 |
| Website | https://www.astrazeneca.co.kr/ | soohee.park@astrazeneca.com | |
Founded in 1999 through the merger of Sweden's Astra and Britain's Zeneca, AstraZeneca Korea is committed to providing medicines that change the lives of patients by going beyond the limits of treatment for incurable diseases that modern therapeutics cannot overcome. It is a global biopharmaceutical company that pursues scientific innovation. AstraZeneca focuses on research and development of specialty pharmaceuticals that can solve serious medical problems around the world in the fields of cancer, cardiovascular, renal and metabolic diseases, and respiratory diseases.
TAGRISSO (Osimertinib) is a targeted therapy for EGFR positive lung cancer. It is an irreversible EGFR Tyrosine Kinase Inhibitor(TKI) with activity against both activating EGFR mutations and T790M resistance mutations, and the ability to cross the blood brain barrier. EGRF TKIs are the only therapies that are FDA-approved as a first treatment for metastatic EGFR positive lung cancer.
IMFINZI (Durvalumab) has proven efficacy and safety for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy and for the first-line treatment of adult patients with extensive-stage small cell lung cancer in combination with etoposide and either carboplatin or cisplatin, is indicated (ES-SCLC).
